Annovis Bio Financials
| ANVS Stock | USD 6.71 0.17 2.60% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.27 | 2.3856 |
|
|
Investors should never underestimate Annovis Bio's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Annovis Bio's cash flow, debt, and profitability to make informed and accurate decisions about investing in Annovis Bio.
Net Income |
|
Annovis | Select Account or Indicator |
Understanding current and past Annovis Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Annovis Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Annovis Bio's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Annovis Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Annovis Bio. Check Annovis Bio's Beneish M Score to see the likelihood of Annovis Bio's management manipulating its earnings.
Annovis Bio Stock Summary
Annovis Bio competes with Cassava Sciences, Axsome Therapeutics, Reviva Pharmaceuticals, Seres Therapeutics, and Anavex Life. Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 3 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | New York Stock Exchange |
| ISIN | US03615A1088 |
| CUSIP | 03615A108 |
| Location | Pennsylvania; U.S.A |
| Business Address | 101 Lindenwood Drive, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.annovisbio.com |
| Phone | (484) 875 3192 |
| Currency | USD - US Dollar |
Annovis Bio Key Financial Ratios
| Return On Equity | -5.97 | ||||
| EBITDA | (45.04 M) | ||||
| Net Income | (56.2 M) | ||||
| Cash Per Share | 4.41 X | ||||
| Debt To Equity | (0.31) % |
Annovis Bio Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 1.1M | 8.1M | 46.0M | 36.0M | 10.2M | 14.9M | |
| Other Current Liab | 776.9K | 236.5K | 818.4K | 3.7M | 3.0M | 3.1M | |
| Net Tangible Assets | (7.6M) | (8.6M) | 7.5M | 44.5M | 51.2M | 53.7M | |
| Retained Earnings | (8.8M) | (14.2M) | (28.7M) | (54.1M) | (110.3M) | (104.7M) | |
| Accounts Payable | 1.2M | 341.9K | 688.1K | 4.0M | 1.3M | 1.5M | |
| Cash | 1.9K | 8.1M | 45.7M | 28.4M | 5.8M | 9.4M | |
| Other Current Assets | 745.7M | 38.2K | 72.8K | 104.9K | 4.5M | 4.2M | |
| Total Liab | 9.7M | 578.4K | 1.5M | 7.7M | 18.0M | 18.9M | |
| Total Current Assets | 747.5K | 8.1M | 46.0M | 36.0M | 10.2M | 12.9M | |
| Net Debt | 497.9K | (8.1M) | (45.7M) | (28.4M) | (5.8M) | (6.0M) | |
| Capital Surpluse | 192.1K | 200.6K | 21.8M | 73.2M | 84.2M | 88.4M | |
| Net Invested Capital | (8.1M) | 7.5M | 44.5M | 28.3M | (7.8M) | (7.4M) | |
| Net Working Capital | (1.3M) | 7.5M | 44.5M | 28.3M | 5.9M | 5.6M |
Annovis Bio Key Income Statement Accounts
The reason investors look at the income statement is to determine what Annovis Bio's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 40.9M | 47.2M | 13.3K | 182.7K | 210.1K | 199.6K | |
| Operating Income | (1.6M) | (6.6M) | (14.5M) | (25.5M) | (45.0M) | (42.8M) | |
| Ebit | (1.6M) | (12.1M) | (29.0M) | (25.5M) | (45.0M) | (42.8M) | |
| Income Before Tax | (991.0K) | (5.5M) | (14.5M) | (25.3M) | (56.2M) | (53.4M) | |
| Net Income | (296.8K) | (4.3M) | (14.4M) | (25.1M) | (56.2M) | (53.4M) | |
| Income Tax Expense | (694.1K) | (1.2M) | (50.1K) | (182.7K) | (45.0K) | (47.3K) | |
| Net Interest Income | (40.9K) | 47.2K | 13.3K | 182.7K | 675.9K | 709.7K | |
| Research Development | 776.3K | 3.1M | 8.5M | 16.5M | 38.8M | 40.7M | |
| Ebitda | (791.0K) | (5.5M) | (14.5M) | (25.5M) | (45.0M) | (42.8M) |
Annovis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Annovis Bio's current stock value. Our valuation model uses many indicators to compare Annovis Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Annovis Bio competition to find correlations between indicators driving Annovis Bio's intrinsic value. More Info.Annovis Bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Annovis Bio's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Annovis Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Annovis Bio Systematic Risk
Annovis Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Annovis Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Annovis Bio correlated with the market. If Beta is less than 0 Annovis Bio generally moves in the opposite direction as compared to the market. If Annovis Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Annovis Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Annovis Bio is generally in the same direction as the market. If Beta > 1 Annovis Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Annovis Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Annovis Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Annovis Bio growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Annovis Bio November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Annovis Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Annovis Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Annovis Bio based on widely used predictive technical indicators. In general, we focus on analyzing Annovis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Annovis Bio's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 21.75 | |||
| Value At Risk | (5.94) | |||
| Potential Upside | 6.62 |
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.